ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

@article{Olaussen2007ERCC1AA,
  title={ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.},
  author={Ken Andr{\'e} Olaussen and Giannis Mountzios and Jean-Charles Soria},
  journal={Current opinion in pulmonary medicine},
  year={2007},
  volume={13 4},
  pages={
          284-9
        }
}
PURPOSE OF REVIEW Cisplatin-based chemotherapy remains the treatment of choice in advanced nonsmall-cell lung cancer. The development of predictive biomarkers able to identify lung-cancer patients who are most likely to benefit from cisplatin-based chemotherapy would be a powerful tool. Many reports have explored the role of ERCC1 expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells. RECENT FINDINGS Using immunohistochemistry in resected tumors, the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 49 CITATIONS

Distribution of nucleotide variants in the DNA sequence of ERCC1 and XRCC1 genes and the effect of phenotype in patients with gastric cancer.

  • The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND